What the April 2026 Announcement Changes The FDA's April 15 announcement signals that injectable GHK-Cu will be removed from the Category 2 list, with formal implementation expected in July 2026 when the FDA's peptide advisory panel is scheduled to reconvene and finalize updated guidance
When you lose that much fat, you likely also lose visceral fat, which is usually the problem fat (this point explored in detail in a recent post)
Goodwin Cartwright, MS Truveta, Inc , Bellevue, WA, Patricia D
Start glowing today, the natural way
#Watch #GLP1 #WeightLossDrugs #PharmaNews #IndianPharma #Semaglutide #Mounjaro #Wegovy #Ozempic #PatentExpiry #HealthcareBusiness #CNBCTV18Digital Transcript To view or add a comment, sign in More Relevant Posts Ozempic patents expire March 2026, triggering 50% price drops in India, China, Brazil